查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198378

智能藥丸藥物輸送市場-增長、趨勢、COVID-19 影響和預測 (2023-2028)

Smart Pills Drug Delivery Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，智能藥丸給藥市場預計將以 10.2% 的複合年增長率增長。

COVID-19 大流行增加了對智能藥丸的需求，以管理患有 COVID-19 和其他相關疾病的患者。 它還刺激了開發智能藥物的研發活動。 例如，根據 2020 年 8 月發表在 International Journal on Emerging Technologies 上的一篇文章，在 COVID-19 大流行的時代，越來越需要老年人和感染者使用預編程的藥丸給藥系統。需要發展。 這裡提出的預編程藥丸分配器 (PPD) 就是這樣一種方法，旨在讓用戶定期服藥。 所提出的預編程給藥系統設計有使用警報和攝像頭單元的警告模塊。 這是旨在幫助患者定期服藥的方法之一，而發展中國家的家庭保健成本要高得多，這使得個人尋求具有成本效益的解決方案。據說這是一個導火索。 因此，據觀察，所研究的市場受到上述因素的積極影響。

推動智能藥丸給藥市場增長的某些因素包括對微創設備的偏好增加、胃腸道疾病發病率增加以及技術進步。 此外，神經系統疾病、癌症和其他疾病日益加重的負擔正在推動醫療環境中對智能平板電腦的需求。 例如，根據世界衛生組織 2021 年 9 月更新，約有 5500 萬人患有癡呆症，其中超過 60% 生活在低收入和中等收入國家。 同一份文件還報告說，這一數字預計到 2030 年將增加到 7800 萬，到 2050 年將增加到 1.39 億。 隨著阿爾茨海默病和癡呆患者的增加，忘記吃藥或誤服的可能性越來越大，對智能藥丸和藥物輸送的需求越來越大。 因此，全球不斷增加的疾病負擔和日益增長的護理需求正在推動市場研究。

根據 GIE Media Co., Ltd. 2021 年 12 月發表的一篇文章，需要使用特殊工具來執行需要高級技能的動作，這些工具的可見性和運動範圍有限，因此手術團隊引入了更高水平的的專業知識。 輔助設備包括內窺鏡照相機、可視化掃描儀和造影劑注射器。 根據 2020 年 1 月發表在 JAMA Network 上的一篇論文，由於與傳統開放手術技術相比具有優勢，大多數外科醫生現在更喜歡高度微創的手術，例如腹腔鏡單切口手術 (LESS)，從而選擇手術技術。 這些好處包括更少的疤痕和組織損傷、更快的恢復、更短的住院時間、更少的出血和創傷、更低的感染風險以及更低的整體醫療保健成本。 此外，在一些國家，醫療保險越來越多地涵蓋微創手術。 這些因素增加了患者對微創手術的偏好，導致智能藥丸給藥市場的增長。

因此，上述因素共同歸因於所研究的市場在預測期內的增長。 然而，預計在預測期內，批准智能藥丸的嚴格法規和潛在的健康風險將阻礙市場增長。

智能藥丸給藥市場趨勢

分類型來看，膠囊內鏡有望佔據較大市場份額

膠囊內窺鏡檢查是一種使用小型無線攝像頭拍攝消化道照片的程序。 膠囊內窺鏡攝像頭裝在一個維生素大小的膠囊中，您可以吞嚥。 當膠囊穿過消化道時，相機拍攝了數千張照片並將它們發送到腰帶上的記錄儀。 隨著醫療保健技術的進步，智能藥丸可以消除侵入性手術的需要。 在智能藥物方面取得了各種進展，例如電池和板載存儲器，它們對於長期使用也具有意義。 根據 2022 年 3 月發表在 Gastroenterology & Endoscopy News 上的一篇文章，膠囊內鏡在評估 GI 出血方面具有較高的陽性（94%-97%）和陰性（83%-100%）預測價值，內鏡檢查結果可能導致內鏡或手術37% 至 87% 的患者進行干預或改變醫療管理。 因此，由於內窺鏡檢查領域的不斷進步以及胃腸道疾病 (GI) 患病率的增加以及對正確診斷的需求，預計所研究的市場在預測期內將出現快速增長。被認為

由於全球公司傾向於智能膠囊，預計該細分市場將呈現健康增長。 例如，Medtronic 有 PillCam SB1 和 PillCam SB2，Olympus 有 Endocapsule 和 Endocapsule 10，NaviCam Stomach 是 Ankon 開發的，而 CapsoVision 則在全球市場提供 CapsoCam。 市場上的先進技術和產品批准也有望推動該領域的增長。 例如，2021 年 11 月，美敦力公司宣布美國食品和藥物管理局 (FDA) 批准用於遠程內窺鏡手術的 PillCam Small Bowel 3 系統。 此外，2022 年 7 月，蘇格蘭衛生研究人員將啟動一項耗資 600 萬歐元的新項目，使人工智能輔助 (AI) 膠囊內窺鏡成為未來腸癌診斷的一部分。 臨床膠囊內窺鏡檢查 (CCE) 使用一種包含攝像頭的“智能藥丸”，當患者吞服該攝像頭時，它會記錄通過腸道的圖像。

因此，上述因素預計將在預測期內推動市場的細分增長。

北美主導市場，預計在預測期內也會如此

由於以下因素，北美佔據了全球市場的大部分份額，例如廣泛接受先進的解決方案以簡化患者護理、龐大的客戶群以及快速增長的老年人口。

由於人為乾預特殊藥物輸送而導致的用藥錯誤增加可能會導致快速增長，並且需要專注於為美國患者提供基於價值的護理。 根據國家醫學圖書館發表的一篇論文，到 2022 年 7 月，僅在美國，每年將有 7,000 至 9,000 人死於用藥錯誤。 此外，數以百萬計的人有他們通常不會透露的副作用和其他藥物問題。 根據美國食品和藥物管理局 (FDA) 的數據，到 2020 年，美國每年報告的疑似用藥錯誤超過 100,000 起。 因此，這一統計數據表明，該國對智能藥丸產品的需求越來越大，以避免用藥錯誤。

根據 2022 年阿爾茨海默病事實與數據報告，超過 600 萬各年齡段的美國人患有阿爾茨海默病，到 2022 年，65 歲以上的美國人將有 650 萬患有阿爾茨海默病。據估計，一個人與阿爾茨海默氏病。 同一份數據顯示，美國65歲及以上總人口中約每9人中就有1人（10.7%）患有阿爾茨海默病，而65至74歲的人中有5.0%隨著年齡增長而患阿爾茨海默病。據報導，有的人 因此，從統計數據來看，美國對智能藥丸的需求預計會增長。

智能藥丸給藥市場的競爭對手分析

由於多家公司在全球和區域開展業務，智能藥丸給藥市場得到了整合。 競爭格局包括 CapsoVision、Check-Cap、etectRx Inc、HQ Inc、金山科技、Koninklijke Philips NV (Medimetrics)、Medtronic PLC、Olympus Medical Technology、Otsuka Pharmaceutical、Proteus Pharmaceuticals、Intermedic 等。包括分析幾種高-簡介國際和區域公司。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 越來越喜歡微創設備
    • 慢性病發病率增加
    • 技術進步
  • 市場製約因素
    • 智能藥丸審批的嚴格規定
    • 潛在的健康風險
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分

  • 類型
    • 膠囊內窺鏡檢查
    • 病人監護
    • 藥物輸送系統
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • CapsoVision
    • Check-Cap
    • etectRx Inc.
    • HQ Inc.
    • Jinshan Science and Technology
    • Koninklijke Philips NV（Medimetrics）
    • Medtronic PLC
    • Olympus Medical Technology
    • Otsuka Pharmaceutical Co. Ltd
    • Intromedic

第7章 市場機會與今後動向

簡介目錄
Product Code: 51919

The Smart Pills Drug Delivery Market is expected to register a CAGR of 10.2% over the forecast period.

The COVID-19 pandemic has boosted the demand for smart pills for managing patients suffering from COVID-19 and other associated disorders. It has also fueled the research and development activities for developing smart drugs. For instance, as per an article published by the International Journal on Emerging Technologies, in August 2020, in times of the COVID-19 pandemic, there was a need to develop a pill drug delivery system with a preprogrammed feature that will be used by the elderly or infected people. The proposed preprogrammed pill dispenser (PPD) is one such approach that is designed to help them to take their medicines at regular intervals of time. It states that the proposed preprogrammed drug delivery system is designed with an alerting module using an alarm and camera unit, which is one such approach intended to help patients take their medications at regular intervals as the in-home medical care cost in a developing country is much higher, which leads the individual to think of a cost-effective solution. Hence, with the abovementioned factors, it is observed that the market studied was positively impacted.

Specific factors driving the smart pills drug delivery market growth include increasing preference for minimally invasive devices, increasing incidence of gastrointestinal disorders, and technological advancements. Additionally, the increasing burden of neurological, cancer and other diseases drives the demand for intelligent pills in healthcare settings. For instance, according to the World Health Organization September 2021 update, around 55 million people have dementia, with over 60% living in low and middle-income countries. The same source also reports that this number is expected to rise to 78 million in 2030 and 139 million in 2050. With the increasing cases of Alzheimer's and dementia, there are increased chances of missing doses of medication or wrong administration of it, increasing the need for smart pills and drug delivery. Thus, the increasing burden of diseases around the globe and the need for care drives the market studied.

According to an article published by GIE Media, Inc., in December 2021, the need to perform highly skilled actions using specialized tools with limited visibility and motion range has introduced higher levels of expertise for surgical teams. Support equipment includes endoscopic cameras, visualization scanners, contrast injectors, etc. According to an article published on JAMA Network in January 2020, most surgeons currently opt for advanced minimally invasive surgical procedures such as laparo-endo single-incision surgery (LESS) due to their advantages over traditional open surgical techniques. These advantages include fewer scars and tissue injury, quicker recovery periods, shorter hospital stays, reduced blood loss and trauma, lower risk of infection, and reduced overall healthcare costs. In addition, minimally invasive surgeries are increasingly being covered by health insurance providers in selected countries. These factors have led to an increased preference for minimally invasive surgeries among patients leading to the growth of the smart pills drug delivery market.

Therefore, the abovementioned factors are attributed collectively to the studied market growth over the forecast period. However, stringent regulations for approving smart pills and potential health risks are expected to hinder market growth over the forecast period.

Smart Pills Drug Delivery Market Trends

Capsule Endoscopy is Expected to Hold Significant Market Share in the Type Segment

Capsule endoscopy is a procedure that uses a tiny wireless camera to take pictures of your digestive tract. A capsule endoscopy camera sits inside a vitamin-size capsule you swallow. As the capsule travels through your digestive tract, the camera takes thousands of pictures transmitted to a recorder you wear on a belt around your waist. With the advent of healthcare technology, smart pills can eliminate the need for invasive procedures. Various advances are being undertaken in smart drugs, such as batteries and onboard memory, making them significant for long-term usage. According to an article published by Gastroenterology & Endoscopy News in March 2022, capsule endoscopy has a high positive (94%-97%) and negative (83%-100%) predictive value in the evaluation of GI bleeding, and findings on capsule endoscopy can lead to endoscopic or surgical intervention or a change in medical management in 37% to 87% of patients. Hence, with the continuous advancements that are being made in the area of endoscopy, and with the rising in gastrointestinal disorders (GI) and the need for proper diagnosis, it is believed that the market studied will have rapid growth over the forecast period.

The segment is expected to witness healthy growth due to the global companies inclining toward the smart capsule. For instance, Medtronic provides PillCam SB1 and PillCam SB2, Olympus provides Endocapsule and Endocapsule 10, NaviCam Stomach is developed by Ankon, whereas, CapsoVision provides CapsoCam in the global markets. Advanced technologies and product approvals in the market are also expected to drive segment growth. For instance, In November 2021, Medtronic plc announced the United States Food and Drug Administration (FDA) clearance for its PillCam Small Bowel 3 system for remote endoscopy procedures. Additionally, in July 2022, Scottish health researchers launched a new EUR 6 million project to make Artificial Intelligence-assisted (AI) capsule endoscopy a part of future bowel cancer diagnostics. Clinical Capsule Endoscopy (CCE) utilizes a 'smart pill' containing cameras that, once swallowed by a patient, records images of the intestines as it passes through.

Therefore, the factors mentioned above are expected to drive segmental growth in the market during the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America has dominated the global market studied, owing to the factors, such as the wide acceptance of technologically advanced solutions to make patient care hassle-free, a large pool of customers, and a rapidly growing geriatric population.

A growing number of medication errors due to human intervention in specialty drug delivery may result in steep upward growth, which requires the need to focus on providing value-based care to patients in the United States. As per an article published by the National Library of Medicine, in July 2022, 7,000 to 9,000 persons each year in the United States alone die as a result of drug mistakes. Additionally, millions of additional people have adverse reactions or other pharmaceutical issues but frequently fail to disclose them. According to the United States Food and Drug Administration (FDA), in 2020, it was found that every year more than 100,000 cases of suspected medication errors are reported in the United States. Thus, the statistics indicate that there has been a rising need for smart pill products in the country to avoid medication errors.

As per the 2022 Alzheimer's Disease facts and figures report, more than 6 million Americans of all ages have Alzheimer's and an estimated 6.5 million Americans aged 65 and older are living with Alzheimer's in 2022. The same source reports that out of the total US population, about 1 in 9 people (10.7%) age 65 and older has Alzheimer's dementia and the percentage of people with Alzheimer's dementia increases with age, 5.0% of people aged 65 to 74. Thus, the statistics indicate that the demand for smart pills is expected to rise in the United States.

Smart Pills Drug Delivery Market Competitor Analysis

The Smart Pills Drug Delivery market is consolidated due to the presence of several companies operating globally and regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known, including CapsoVision, Check-Cap, etectRx Inc., HQ Inc., Jinshan Science and Technology, Koninklijke Philips NV (Medimetrics), Medtronic PLC, Olympus Medical Technology, Otsuka Pharmaceutical Co. Ltd, Proteus Pharmaceuticals, and Intromedic, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Preference for Minimally Invasive Devices
    • 4.2.2 Increasing Incidence of Chronic Disorders
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations for the Approval of Smart Pills
    • 4.3.2 Potential Health Risk
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Type
    • 5.1.1 Capsule Endoscopy
    • 5.1.2 Patient Monitoring
    • 5.1.3 Drug and Delivery Systems
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 CapsoVision
    • 6.1.2 Check-Cap
    • 6.1.3 etectRx Inc.
    • 6.1.4 HQ Inc.
    • 6.1.5 Jinshan Science and Technology
    • 6.1.6 Koninklijke Philips NV (Medimetrics)
    • 6.1.7 Medtronic PLC
    • 6.1.8 Olympus Medical Technology
    • 6.1.9 Otsuka Pharmaceutical Co. Ltd
    • 6.1.10 Intromedic

7 MARKET OPPORTUNITIES AND FUTURE TRENDS